Ciclesonide for the treatment of seasonal allergic rhinitis.
Allergic rhinitis is considered one of the most common afflictions of humans, affecting up to 30% of the world's population, and is increasing in incidence. Primary symptoms, comorbid conditions and complications of this disorder exact a significant toll, resulting in an enormous physical, social and economic impact on society. Single-season allergic rhinitis accounts for approximately 20% of cases of allergic rhinitis with another 40% having mixed seasonal-perennial presentations. Management of this disorder encompasses several treatment options, with intranasal corticosteroids recommended as first-line treatment in moderate-to-severe seasonal allergic rhinitis in current practice parameters. Ciclesonide is the most recently approved product in this category for the management of seasonal allergic rhinitis and is the subject of this article.
Biogenics Research Institute & Biogenics Research Chamber, 8229 Fredericksburg Road, San Antonio, TX, USA. robert.jacobs7025@sbcglobal.net
Robert L
RL
Jacobs
D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D011282:Pregnenediones / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology
D018926:Anti-Allergic Agents; D011282:Pregnenediones; C120481:ciclesonide